Opendata, web and dolomites


Normothermic Perfusion Device for Renal and Hepatic Preservation and Viability Assessment

Total Cost €


EC-Contrib. €






Project "NORMOPERF" data sheet

The following table provides information about the project.


Organization address
address: AVENIDA DE MADRID 117 5 A
postcode: 50010
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website
 Total cost 2˙570˙850 €
 EC max contribution 2˙570˙850 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-06-01   to  2020-11-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EBERS MEDICAL TECHNOLOGY SL ES (ZARAGOZA) coordinator 2˙570˙850.00


 Project objective

EBERS is a leading company in the field of bioreactors and cell culture systems, with a wide international presence in Europe, USA, Australia, and Asia. In the NORMOPERF project we go a step further by targeting the organ transplantation field by bringing to the healthcare market a new portable device for extracorporeal organ preservation based on a patented technology (P201730030). Organ transplantation is in many cases the only effective therapy for end-stage organ failure. However, it is estimated that only 10% of the global organ needs are covered. Traditionally, only organs obtained in optimal conditions have been considered for transplantation. However, organ lack is leading to the increased use of suboptimal grafts (e.g. non-heart beating donors), which poses new challenges. The most important hurdle preventing the clinical use of suboptimal organs is the limitation of static cold preservation (SCP). SCP is well suited for optimal grafts, but not for suboptimal ones since (i) it allows short preservation times (2-20 h), (ii) it does not provide information about the organ viability and (iii) it additionally damages the organ due to ischemia-reperfusion. The solution proposed by EBERS is a new portable medical device based on normothermic perfusion, capable of maintaining human organs in a viable state for sustained periods under physiological conditions. The NORMOPERF project will offer the clinical community a new device for organ preservation that will contribute to increasing the number of organs available for transplantation by making possible the clinical use of a significant part of the suboptimal organs that are currently not even considered for transplantation. Thus, the use of our technology will allow increasing x2-3 the current transplant rates in the short term. According to our conservative estimations, the €2.57 Mill required for this project will mean €21.3M cumulative EBITDA in 5-years, representing a ROI of 723%.


List of deliverables.
Webpage Websites, patent fillings, videos etc. 2019-10-28 17:54:42

Take a look to the deliverables list in detail:  detailed list of NORMOPERF deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NORMOPERF" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NORMOPERF" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More